AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Your search for apixaban returned 46 results
Drugs in the Pipeline
Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
AHA 2015
Apixaban vs. Warfarin: Effects Compared in AF Patients With, Without PAD
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
AHA 2017 Scientific Sessions
Does Use of Apixaban With Cardiac P-gp Inhibitors Up Bleeding Risk?
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.
News
Is Apixaban an Appropriate Alternative to Warfarin in Patients with Severe Renal Impairment?
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
News
First Generics of Eliquis Receive Approval
The Food and Drug Administration (FDA) has approved the first generics of Eliquis (apixaban; Bristol-Myers Squibb and Pfizer) tablets. Apixaban, a factor Xa inhibitor, is indicated: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism…
ESC 2017
Apixaban Compared to Standard Care in NVAF Patients Undergoing Cardioversion
This is an investigational use for Eliquis.
News
Apixaban Dosing Examined in Patients With Only One-Dose Reduction Criterion
For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.
News
Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
